Literature DB >> 12692111

Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk.

Wei Zhou1, Geoffrey Liu, David P Miller, Sally W Thurston, Li Lian Xu, John C Wain, Thomas J Lynch, Li Su, David C Christiani.   

Abstract

XRCC1 (X-ray cross-complementing group 1) and ERCC2 (excision repair cross-complementing group 2) are two major DNA repair proteins. Polymorphisms of these two genes have been associated with altered DNA repair capacity and cancer risk. We have described statistically significant interactions between the ERCC2 polymorphisms (Asp312Asn and Lys751Gln) and smoking in lung cancer risk. In this case-control study of 1091 Caucasian lung cancer patients and 1240 controls, we explored the gene-environment interactions between the XRCC1 Arg399Gln polymorphism, alone or in combination with the two ERCC2 polymorphisms, and cumulative smoking exposure in the development of lung cancer. The results were analyzed using logistic regression models, adjusting for relevant covariates. Overall, the adjusted odds ratio (OR) of XRCC1 Arg399Gln polymorphism (Gln/Gln versus Arg/Arg) was 1.3 [95% confidence interval (CI), 1.0-1.8]. Stratified analyses revealed that the ORs decreased as pack-years increased. For nonsmokers, the adjusted OR was 2.4 (95% CI, 1.2-5.0), whereas for heavy smokers (>/=55 pack-years), the OR decreased to 0.5 (95% CI, 0.3-1.0). When the three polymorphisms were evaluated together, the adjusted ORs of the extreme genotype combinations of variant alleles (individuals with 5 or 6 variant alleles) versus wild genotype (individuals with 0 variant alleles) were 5.2 (95% CI, 1.7-16.6) for nonsmokers and 0.3 (95% CI, 0.1-0.8) for heavy smokers, respectively. Similar gene-smoking interaction associations were found when pack-years of smoking (or smoking duration and smoking intensity) was fitted as a continuous variable. In conclusion, cumulative cigarette smoking plays an important role in altering the direction and magnitude of the associations between the XRCC1 and ERCC2 polymorphisms and lung cancer risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692111

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  51 in total

1.  XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies.

Authors:  Liping Dai; Fujiao Duan; Peng Wang; Chunhua Song; Kaijuan Wang; Jianying Zhang
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Wenlong Zhai; Ruo Feng; Haiyu Wang; Yadong Wang
Journal:  Tumour Biol       Date:  2015-04-03

3.  Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients.

Authors:  So-Yeon Park; Yun-Chul Hong; Jin-Hee Kim; Seung-Min Kwak; Jae-Hwa Cho; Hong-Lyeol Lee; Jeong-Seon Ryu
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy.

Authors:  Angeline S Andrew; Margaret R Karagas; Heather H Nelson; Simonetta Guarrera; Silvia Polidoro; Sara Gamberini; Carlotta Sacerdote; Jason H Moore; Karl T Kelsey; Eugene Demidenko; Paolo Vineis; Giuseppe Matullo
Journal:  Hum Hered       Date:  2007-09-26       Impact factor: 0.444

Review 5.  [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

Authors:  Wolfgang Hilbe; Kurt Aigner; Christian Dittrich; Josef Eckmayr; Michael Fiegl; Martin Flicker; Bernhard Forstner; Richard Greil; Herbert Jamnig; Gerhard Krajnik; Alois Lang; Andrea Mohn-Staudner; Herwig Schinko; Michael Studnicka; Robert Pirker; Ferdinand Ploner; Johannes Rothmund; Lothar Schiller; August Zabernigg; Sabine Zöchbauer-Müller
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

6.  A variant of the Cockayne syndrome B gene ERCC6 confers risk of lung cancer.

Authors:  Zhongning Lin; Xuemei Zhang; Jingsheng Tuo; Yongli Guo; Bridgett Green; Chi-Chao Chan; Wen Tan; Ying Huang; Wenhua Ling; Fred F Kadlubar; Dongxin Lin; Baitang Ning
Journal:  Hum Mutat       Date:  2008-01       Impact factor: 4.878

7.  Carcinogenesis-related changes in iron metabolism in chronic obstructive pulmonary disease subjects with lung cancer.

Authors:  Kamil Brzóska; Teresa Bartłomiejczyk; Barbara Sochanowicz; Magdalena Cymerman; Jacek Grudny; Jacek Kołakowski; Marcin Kruszewski; Paweł Śliwiński; Kazimierz Roszkowski-Śliż; Lucyna Kapka-Skrzypczak
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

8.  Genetic Polymorphisms of X-ray Repair Cross-Complementing Group 1 and Apurinic/Apyrimidinic Endonuclease-1 in Chronic Obstructive Pulmonary Disease.

Authors:  Avinash Bardia; Sandeep Kumar Vishwakarma; Chandrakala Lakki Reddy; N Raju; Shaik Iqbal; Gallapalli Sravani; Narneni Lavanya; Nazima Begum; Naziya Usma; Pratibha Nallari; Syed Mehmood Ahmed; Asfaq Hasan; Aleem A Khan
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

9.  Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.

Authors:  Leelakumari Sreeja; Volga S Syamala; Vani Syamala; Sreedharan Hariharan; Praveenkumar B Raveendran; R V Vijayalekshmi; Jayaprakash Madhavan; Ravindran Ankathil
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-19       Impact factor: 4.553

10.  Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.

Authors:  Zhihua Yin; Baosen Zhou; Qincheng He; Mingchuan Li; Peng Guan; Xuelian Li; Zeshi Cui; Xiaoxia Xue; Meng Su; Rui Ma; Weijun Bai; Shuyue Xia; Yanduo Jiang; Shun Xu; Yi Lv; Xun Li
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.